Find trials
Search tips

Extracellular Vesicle Cargo During Type 1 Diabetes Progression

Overview

About this study

This study aims to identify an early stage biomarker for type 1 diabetes. In vitro evidence identified a significant enrichment of the chemokine CXCL10 in β-cell derived EXO upon exposure to diabetogenic pro-inflammatory cytokines. The study also aims to test protocols for efficient isolation of plasma-derived EXO from small volumes of sample, develop an assay for the sensitive detection of CXCL10 in plasma-derived EXO, and characterization of plasma-derived EXO through assessment of concentration, size, and content (proteomics).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of Type 1 Diabetes Mellitus.

Exclusion Criteria: 

  • Diagnosis of Diabetic Nephropathy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Open for enrollment

Contact information:

Jeanette Laugen

(507) 255-8110

Laugen.Jeanette@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20521068

Mayo Clinic Footer